{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T23:14:30Z","timestamp":1787354070041,"version":"build-2736575974"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1-2","license":[{"start":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T00:00:00Z","timestamp":1491350400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cell Biochem"],"published-print":{"date-parts":[[2017,9]]},"DOI":"10.1007\/s11010-017-3011-3","type":"journal-article","created":{"date-parts":[[2017,4,5]],"date-time":"2017-04-05T16:38:39Z","timestamp":1491410319000},"page":"1-12","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Silencing of Y-box binding protein-1 by RNA interference inhibits proliferation, invasion, and metastasis, and enhances sensitivity to cisplatin through NF-\u03baB signaling pathway in human neuroblastoma SH-SY5Y cells"],"prefix":"10.1007","volume":"433","author":[{"given":"Hong","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruowen","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuofei","family":"Chi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuang","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangchun","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,4,5]]},"reference":[{"key":"3011_CR1","first-page":"659","volume":"75","author":"JC Hoehner","year":"1996","unstructured":"Hoehner JC, Gestblom C, Hedborg F et al (1996) A developmental model of neuroblastoma: differentiating stroma-poor tumors\u2019 progress along an extra-adrenal chromaffin lineage. Lab Investig J Tech Methods Pathol 75:659\u2013675","journal-title":"Lab Investig J Tech Methods Pathol"},{"key":"3011_CR2","doi-asserted-by":"crossref","first-page":"2202","DOI":"10.1056\/NEJMra0804577","volume":"362","author":"JM Maris","year":"2010","unstructured":"Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362:2202\u20132211","journal-title":"N Engl J Med"},{"key":"3011_CR3","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ejca.2006.05.008","volume":"42","author":"C Spix","year":"2006","unstructured":"Spix C, Pastore G, Sankila R et al (2006) Neuroblastoma incidence and survival in European children (1978\u20131997): report from the automated childhood cancer information system project. Eur J Cancer 42:2081\u20132091","journal-title":"Eur J Cancer"},{"key":"3011_CR4","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1200\/JCO.1991.9.6.962","volume":"9","author":"G Dini","year":"1991","unstructured":"Dini G, Lanino E, Garaventa A et al (1991) Myeloablative therapy and unpurged autologous bone marrow transplantation for poor-prognosis neuroblastoma: report of 34 cases. J Clin Oncol 9:962\u2013969","journal-title":"J Clin Oncol"},{"issue":"Suppl 4","key":"3011_CR5","first-page":"42","volume":"4","author":"G Dini","year":"1989","unstructured":"Dini G, Philip T, Hartmann O et al (1989) Bone marrow transplantation for neuroblastoma: a review of 509 cases. EBMT Group. Bone Marrow Transplant 4(Suppl 4):42\u201346","journal-title":"Bone Marrow Transplant"},{"key":"3011_CR6","first-page":"865","volume":"16","author":"HY Du","year":"2005","unstructured":"Du HY, Olivo M, Chen YJ et al (2005) Expression of Y-box binding protein-1 following hypericin-mediated photodynamic therapy in well-differentiated nasopharyngeal cancer in vivo. Int J Mol Med 16:865\u2013868","journal-title":"Int J Mol Med"},{"key":"3011_CR7","first-page":"3151","volume":"7","author":"K Shibahara","year":"2001","unstructured":"Shibahara K, Sugio K, Osaki T et al (2001) Nuclear expression of the Y-box binding protein, YB-1, as a novel marker of disease progression in non-small cell lung cancer. Clin Cancer Res 7:3151\u20133155","journal-title":"Clin Cancer Res"},{"key":"3011_CR8","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1002\/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U","volume":"85","author":"T Kamura","year":"1999","unstructured":"Kamura T, Yahata H, Amada S et al (1999) Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? Cancer 85:2450\u20132454","journal-title":"Cancer"},{"key":"3011_CR9","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1042\/BJ20121323","volume":"449","author":"A Lasham","year":"2013","unstructured":"Lasham A, Print CG, Woolley AG et al (2013) YB-1: oncoprotein, prognostic marker and therapeutic target? Biochem J 449:11\u201323","journal-title":"Biochem J"},{"key":"3011_CR10","first-page":"1239","volume":"30","author":"R Wachowiak","year":"2010","unstructured":"Wachowiak R, Thieltges S, Rawnaq T et al (2010) Y-box-binding protein-1 is a potential novel tumour marker for neuroblastoma. Anticancer Res 30:1239\u20131242","journal-title":"Anticancer Res"},{"key":"3011_CR11","doi-asserted-by":"crossref","first-page":"e0127224","DOI":"10.1371\/journal.pone.0127224","volume":"10","author":"H Wang","year":"2015","unstructured":"Wang H, Sun R, Gu M et al (2015) shRNA-mediated silencing of Y-box binding protein-1 (YB-1) suppresses growth of neuroblastoma cell SH-SY5Y in vitro and in vivo. PLoS ONE 10:e0127224","journal-title":"PLoS ONE"},{"key":"3011_CR12","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1002\/(SICI)1097-0215(19991210)83:6<732::AID-IJC6>3.0.CO;2-#","volume":"83","author":"K Shibao","year":"1999","unstructured":"Shibao K, Takano H, Nakayama Y et al (1999) Enhanced coexpression of YB-1 and DNA topoisomerase II alpha genes in human colorectal carcinomas. Int J Cancer 83:732\u2013737","journal-title":"Int J Cancer"},{"key":"3011_CR13","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.2147\/OTT.S99939","volume":"9","author":"S Zhao","year":"2016","unstructured":"Zhao S, Guo W, Li J et al (2016) High expression of Y-box-binding protein 1 correlates with poor prognosis and early recurrence in patients with small invasive lung adenocarcinoma. OncoTargets Ther 9:2683\u20132692","journal-title":"OncoTargets Ther"},{"issue":"37","key":"3011_CR14","first-page":"5891558930","volume":"7","author":"JW Ma","year":"2016","unstructured":"Ma JW, Hung CM, Lin YC et al (2016) Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells. Oncotarget 7(37):58915\u201358930","journal-title":"Oncotarget"},{"key":"3011_CR15","doi-asserted-by":"crossref","first-page":"10594","DOI":"10.3390\/ijms130810594","volume":"13","author":"D Chen","year":"2012","unstructured":"Chen D, Wang Y, Zhang K et al (2012) Antisense oligonucleotide against clusterin regulates human hepatocellular carcinoma invasion through transcriptional regulation of matrix metalloproteinase-2 and E-cadherin. Int J Mol Sci 13:10594\u201310607","journal-title":"Int J Mol Sci"},{"key":"3011_CR16","first-page":"4224","volume":"56","author":"T Ohga","year":"1996","unstructured":"Ohga T, Koike K, Ono M et al (1996) Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 56:4224\u20134228","journal-title":"Cancer Res"},{"key":"3011_CR17","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1111\/j.1349-7006.2008.00748.x","volume":"99","author":"Y Oda","year":"2008","unstructured":"Oda Y, Kohashi K, Yamamoto H et al (2008) Different expression profiles of Y-box-binding protein-1 and multidrug resistance-associated proteins between alveolar and embryonal rhabdomyosarcoma. Cancer Sci 99:726\u2013732","journal-title":"Cancer Sci"},{"key":"3011_CR18","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1038\/sj.onc.1208386","volume":"24","author":"U Stein","year":"2005","unstructured":"Stein U, Bergmann S, Scheffer GL et al (2005) YB-1 facilitates basal and 5-fluorouracil-inducible expression of the human major vault protein (MVP) gene. Oncogene 24:3606\u20133618","journal-title":"Oncogene"},{"key":"3011_CR19","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s00432-002-0386-6","volume":"128","author":"H Yahata","year":"2002","unstructured":"Yahata H, Kobayashi H, Kamura T et al (2002) Increased nuclear localization of transcription factor YB-1 in acquired cisplatin-resistant ovarian cancer. J Cancer Res Clin Oncol 128:621\u2013626","journal-title":"J Cancer Res Clin Oncol"},{"key":"3011_CR20","doi-asserted-by":"crossref","first-page":"29396","DOI":"10.18632\/oncotarget.5120","volume":"6","author":"L Prabhu","year":"2015","unstructured":"Prabhu L, Mundade R, Wang B et al (2015) Critical role of phosphorylation of serine 165 of YBX1 on the activation of NF-kappaB in colon cancer. Oncotarget 6:29396\u201329412","journal-title":"Oncotarget"},{"key":"3011_CR21","first-page":"514","volume":"24","author":"AG Knudson","year":"1972","unstructured":"Knudson AG, Strong LC (1972) Mutation and cancer: neuroblastoma and pheochromocytoma. Am J Hum Genet 24:514\u2013532","journal-title":"Am J Hum Genet"},{"key":"3011_CR22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1038\/nature07261","volume":"455","author":"YP Mosse","year":"2008","unstructured":"Mosse YP, Laudenslager M, Longo L et al (2008) Identification of ALK as a major familial neuroblastoma predisposition gene. Nature 455:930\u2013935","journal-title":"Nature"},{"key":"3011_CR23","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nm0497-447","volume":"3","author":"RC Bargou","year":"1997","unstructured":"Bargou RC, Jurchott K, Wagener C et al (1997) Nuclear localization and increased levels of transcription factor YB-1 in primary human breast cancers are associated with intrinsic MDR1 gene expression. Nat Med 3:447\u2013450","journal-title":"Nat Med"},{"key":"3011_CR24","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/ijc.1610","volume":"97","author":"M Janz","year":"2002","unstructured":"Janz M, Harbeck N, Dettmar P et al (2002) Y-box factor YB-1 predicts drug resistance and patient outcome in breast cancer independent of clinically relevant tumor biologic factors HER2, uPA and PAI-1. Int J Cancer 97:278\u2013282","journal-title":"Int J Cancer"},{"key":"3011_CR25","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/pros.20023","volume":"59","author":"P Gimenez-Bonafe","year":"2004","unstructured":"Gimenez-Bonafe P, Fedoruk MN, Whitmore TG et al (2004) YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity. Prostate 59:337\u2013349","journal-title":"Prostate"},{"key":"3011_CR26","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1200\/JCO.2006.07.8626","volume":"25","author":"D Faury","year":"2007","unstructured":"Faury D, Nantel A, Dunn SE et al (2007) Molecular profiling identifies prognostic subgroups of pediatric glioblastoma and shows increased YB-1 expression in tumors. J Clin Oncol 25:1196\u20131208","journal-title":"J Clin Oncol"},{"key":"3011_CR27","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1038\/onc.2015.491","volume":"35","author":"A Dey","year":"2016","unstructured":"Dey A, Robitaille M, Remke M et al (2016) YB-1 is elevated in medulloblastoma and drives proliferation in Sonic hedgehog-dependent cerebellar granule neuron progenitor cells and medulloblastoma cells. Oncogene 35:4256\u20134268","journal-title":"Oncogene"},{"key":"3011_CR28","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1134\/S0006297911130049","volume":"76","author":"IA Eliseeva","year":"2011","unstructured":"Eliseeva IA, Kim ER, Guryanov SG et al (2011) Y-box-binding protein 1 (YB-1) and its functions. Biochem Biokhimiia 76:1402\u20131433","journal-title":"Biochem Biokhimiia"},{"key":"3011_CR29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/nature04872","volume":"441","author":"G Christofori","year":"2006","unstructured":"Christofori G (2006) New signals from the invasive front. Nature 441:444\u2013450","journal-title":"Nature"},{"key":"3011_CR30","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/his.12570","volume":"66","author":"T Guo","year":"2015","unstructured":"Guo T, Yu Y, Yip GW et al (2015) Y-box binding protein 1 is correlated with lymph node metastasis in intestinal-type gastric cancer. Histopathology 66:491\u2013499","journal-title":"Histopathology"},{"key":"3011_CR31","doi-asserted-by":"crossref","first-page":"38239","DOI":"10.18632\/oncotarget.5664","volume":"6","author":"B Castellana","year":"2015","unstructured":"Castellana B, Aasen T, Moreno-Bueno G et al (2015) Interplay between YB-1 and IL-6 promotes the metastatic phenotype in breast cancer cells. Oncotarget 6:38239\u201338256","journal-title":"Oncotarget"},{"key":"3011_CR32","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1002\/ar.22702","volume":"296","author":"TT Guo","year":"2013","unstructured":"Guo TT, Yu YN, Yip GW et al (2013) Silencing the YB-1 gene inhibits cell migration in gastric cancer in vitro. Anat Rec 296:891\u2013898","journal-title":"Anat Rec"},{"key":"3011_CR33","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1517\/14728222.6.2.217","volume":"6","author":"JT Price","year":"2002","unstructured":"Price JT, Thompson EW (2002) Mechanisms of tumour invasion and metastasis: emerging targets for therapy. Expert Opin Ther Targets 6:217\u2013233","journal-title":"Expert Opin Ther Targets"},{"key":"3011_CR34","doi-asserted-by":"crossref","first-page":"7468","DOI":"10.1038\/sj.onc.1206948","volume":"22","author":"SV Ambudkar","year":"2003","unstructured":"Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE et al (2003) P-glycoprotein: from genomics to mechanism. Oncogene 22:7468\u20137485","journal-title":"Oncogene"},{"key":"3011_CR35","doi-asserted-by":"crossref","first-page":"e71071","DOI":"10.1371\/journal.pone.0071071","volume":"8","author":"BX Zhao","year":"2013","unstructured":"Zhao BX, Sun YB, Wang SQ et al (2013) Grape seed procyanidin reversal of p-glycoprotein associated multi-drug resistance via down-regulation of NF-kappaB and MAPK\/ERK mediated YB-1 activity in A2780\/T cells. PLoS ONE 8:e71071","journal-title":"PLoS ONE"},{"key":"3011_CR36","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/abbs\/gms099","volume":"45","author":"X Zhu","year":"2012","unstructured":"Zhu X, Li Y, Shen H et al (2012) miR-137 restoration sensitizes multidrug-resistant MCF-7\/ADM cells to anticancer agents by targeting YB-1. Acta Biochim Biophys Sin 45:80\u201386","journal-title":"Acta Biochim Biophys Sin"},{"key":"3011_CR37","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.exphem.2011.01.013","volume":"39","author":"H Shen","year":"2011","unstructured":"Shen H, Xu W, Luo W et al (2011) Upregulation of mdr1 gene is related to activation of the MAPK\/ERK signal transduction pathway and YB-1 nuclear translocation in B-cell lymphoma. Exp Hematol 39:558\u2013569","journal-title":"Exp Hematol"},{"key":"3011_CR38","doi-asserted-by":"crossref","first-page":"7537","DOI":"10.1038\/sj.onc.1206953","volume":"22","author":"GD Kruh","year":"2003","unstructured":"Kruh GD, Belinsky MG (2003) The MRP family of drug efflux pumps. Oncogene 22:7537\u20137552","journal-title":"Oncogene"},{"key":"3011_CR39","doi-asserted-by":"crossref","first-page":"7340","DOI":"10.1038\/sj.onc.1206938","volume":"22","author":"L Doyle","year":"2003","unstructured":"Doyle L, Ross DD (2003) Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2). Oncogene 22:7340\u20137358","journal-title":"Oncogene"},{"key":"3011_CR40","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1038\/sj.onc.1205117","volume":"21","author":"MT Kuo","year":"2002","unstructured":"Kuo MT, Liu Z, Wei Y et al (2002) Induction of human MDR1 gene expression by 2-acetylaminofluorene is mediated by effectors of the phosphoinositide 3-kinase pathway that activate NF-kappaB signaling. Oncogene 21:1945\u20131954","journal-title":"Oncogene"},{"key":"3011_CR41","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1053\/jhep.2002.32469","volume":"35","author":"O Fantappie","year":"2002","unstructured":"Fantappie O, Masini E, Sardi I et al (2002) The MDR phenotype is associated with the expression of COX-2 and iNOS in a human hepatocellular carcinoma cell line. Hepatology 35:843\u2013852","journal-title":"Hepatology"},{"key":"3011_CR42","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.clpt.2005.11.013","volume":"79","author":"J Lamba","year":"2006","unstructured":"Lamba J, Strom S, Venkataramanan R et al (2006) MDR1 genotype is associated with hepatic cytochrome P450 3A4 basal and induction phenotype. Clin Pharmacol Ther 79:325\u2013338","journal-title":"Clin Pharmacol Ther"},{"key":"3011_CR43","doi-asserted-by":"crossref","first-page":"20310","DOI":"10.1074\/jbc.M500737200","volume":"280","author":"S Misra","year":"2005","unstructured":"Misra S, Ghatak S, Toole BP (2005) Regulation of MDR1 expression and drug resistance by a positive feedback loop involving hyaluronan, phosphoinositide 3-kinase, and ErbB2. J Biol Chem 280:20310\u201320315","journal-title":"J Biol Chem"},{"key":"3011_CR44","doi-asserted-by":"crossref","first-page":"15174","DOI":"10.1074\/jbc.272.24.15174","volume":"272","author":"G Zhou","year":"1997","unstructured":"Zhou G, Kuo MT (1997) NF-kappaB-mediated induction of mdr1b expression by insulin in rat hepatoma cells. J Biol Chem 272:15174\u201315183","journal-title":"J Biol Chem"}],"container-title":["Molecular and Cellular Biochemistry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11010-017-3011-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-017-3011-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11010-017-3011-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,8,12]],"date-time":"2017-08-12T06:23:59Z","timestamp":1502519039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11010-017-3011-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,5]]},"references-count":44,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2017,9]]}},"alternative-id":["3011"],"URL":"https:\/\/doi.org\/10.1007\/s11010-017-3011-3","relation":{},"ISSN":["0300-8177","1573-4919"],"issn-type":[{"value":"0300-8177","type":"print"},{"value":"1573-4919","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,5]]}}}